Arcus Biosciences (RCUS) Tops Q4 EPS by 22c

Arcus Biosciences (NYSE: RCUS) reported Q4 EPS of ($0.93), $0.22 better than the analyst estimate of ($1.15). Revenue for the quarter came in at $34 million versus the consensus estimate of $22.59 million.

For earnings history and earnings-related data on Arcus Biosciences (RCUS) click here.

You May Also Be Interested In

• JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
• NXP Semiconductors names Mike Lucarelli as new investor relations head
• Crown Crafts (CRWS) Reports Q4 EPS of $0.03